Hypoxia-responsive copolymer for siRNA delivery

Methods in Molecular Biology

Volumn 1372, Issue , 2016, Pages 139-162

  Perche, Federico ^a   Biswas, Swati ^a   Patel, Niravkumar R ^a   Torchilin, Vladimir P ^a  

^a NONE

Author keywords

Azobenzene; SiRNA delivery; Stimuli sensitive; Tumor hypoxia; Tumor targeting

Indexed keywords

AZOBENZENE; COPOLYMER; DIOLEYL PHOSPHATIDYLINOSITOL; LIPID; MACROGOL 2000; PHOSPHATIDYLINOSITOL; POLYELECTROLYTE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; POLYMER;

ANIMAL CELL; CANCER CELL; CHEMISTRY; CONJUGATE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; EXPERIMENTAL MODEL; FEMALE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MONOLAYER CULTURE; MOUSE; NEOPLASM; NONHUMAN; PURIFICATION; RECEPTOR DOWN REGULATION; REPORTER GENE; TUMOR SPHEROID; TUMOR XENOGRAFT; ANIMAL; ANOXIA; CELL CULTURE TECHNIQUE; CELL HYPOXIA; DISEASE MODEL; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE SILENCING; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; NEOPLASMS; PROCEDURES; RNA INTERFERENCE; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANOXIA; CELL CULTURE TECHNIQUES; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENE TRANSFER TECHNIQUES; GENES, REPORTER; HETEROGRAFTS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICROSCOPY, FLUORESCENCE; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; POLYMERS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 84946552552     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3148-4_12     Document Type: Chapter

References (42)

1. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG (2012) Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12(1):39–50. doi:10.1038/nrc3180
2. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA 3rd (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3(4):406–417. doi:10.1158/2159-8290.CD-12-0429
3. Hrkach J, Von HoffD, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen HT, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra39. doi:10.1126/scitranslmed.3003651
4. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771–782. doi:10.1038/nrd2614
5. Chow EK, Ho D (2013) Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med 5(216):216. doi:10.1126/scitranslmed.3005872
6. Chauhan VP, Jain RK (2013) Strategies for advancing cancer nanomedicine. Nat Mater 12(11):958–962. doi:10.1038/nmat3792
7. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25. doi:10.1016/j.addr.2013.11.009
8. Caron WP, Morgan KP, Zamboni BA, Zamboni WC (2013) A review of study designs and outcomes of phase I clinical studies of nanoparticle agents compared with small-molecule anticancer agents. Clin Cancer Res 19(12):3309–3315. doi:10.1158/1078-0432.CCR-12-3649
9. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338(6109):903–910. doi:10.1126/science.1226338
10. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME (1996) Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDSrelated Kaposi’s sarcoma. J Clin Oncol 14(8):2353–2364
11. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803. doi:10.1200/JCO.2005.04.937
12. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7(2):243–254
13. Committee AACR, Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ (2013) AACR cancer progress report 2013. Clin Cancer Res 19(Suppl 20):S4–S98. doi:10.1158/1078-0432.CCR-13-2107
14. Chan A, Orme RP, Fricker RA, Roach P (2013) Remote and local control of stimuli responsive materials for therapeutic applications. Adv Drug Deliv Rev 65(4):497–514. doi:10.1016/j.addr.2012.07.007
15. Ge Z, Liu S (2013) Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. Chem Soc Rev 42(17):7289–7325. doi:10.1039/c3cs60048c
16. Chen CY, Kim TH, Wu WC, Huang CM, Wei H, Mount CW, Tian Y, Jang SH, Pun SH, Jen AK (2013) pH-dependent, thermosensitive polymeric nanocarriers for drug delivery to solid tumors. Biomaterials 34(18):4501–4509. doi:10.1016/j.biomaterials.2013.02.049
17. Li Y, Xiao K, Zhu W, Deng W, Lam KS (2014) Stimuli-responsive cross-linked micelles for ondemand drug delivery against cancers. Adv Drug Deliv Rev 66:58–73. doi:10.1016/j.addr.2013.09.008
18. Mura S, Nicolas J, Couvreur P (2013) Stimuliresponsive nanocarriers for drug delivery. Nat Mater 12(11):991–1003. doi:10.1038/nmat3776
19. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, Tsien RY (2010) Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A 107(9):4317–4322. doi:10.1073/pnas.0910261107
20. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY (2010) Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 107(9):4311–4316. doi:10.1073/pnas.0910283107
21. Navarro G, Essex S, Sawant RR, Biswas S, Nagesha D, Sridhar S, de ILarduya CT, Torchilin VP (2014) Phospholipid-modified polyethylenimine-based nanopreparations for siRNA-mediated gene silencing: implications for transfection and the role of lipid components. Nanomedicine 10(2):411–419. doi:10.1016/j.nano.2013.07.016
22. Navarro G, Sawant RR, Biswas S, Essex S, Tros de Ilarduya C, Torchilin VP (2012) P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) 7(1):65–78. doi:10.2217/nnm.11.93
23. Navarro G, Sawant RR, Essex S, Tros de Ilarduya C, Torchilin VP (2011) Phospholipidpolyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv Transl Res 1(1):25–33. doi:10.1007/s13346-010-0004-0
24. Sawant RR, Torchilin VP (2010) Polymeric micelles: polyethylene glycolphosphatidylethanolamine (PEG-PE)-based micelles as an example. Methods Mol Biol 624:131–149. doi:10.1007/978-1-60761-609-2_9
25. Zhu L, Perche F, Wang T, Torchilin VP (2014) Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials 35(13):4213–4222. doi:10.1016/j.biomaterials.2014.01.060
26. Kiyose K, Hanaoka K, Oushiki D, Nakamura T, Kajimura M, Suematsu M, Nishimatsu H, Yamane T, Terai T, Hirata Y, Nagano T (2010) Hypoxia-sensitive fluorescent probes for in vivo real-time fluorescence imaging of acute ischemia. J Am Chem Soc 132(45):15846–15848. doi:10.1021/ja105937q
27. Piao W, Tsuda S, Tanaka Y, Maeda S, Liu F, Takahashi S, Kushida Y, Komatsu T, Ueno T, Terai T, Nakazawa T, Uchiyama M, Morokuma K, Nagano T, Hanaoka K (2013) Development of azo-based fluorescent probes to detect different levels of hypoxia. Angew Chem Int Ed Engl 52(49):13028–13032. doi:10.1002/anie.201305784
28. Krohn KA, Link JM, Mason RP (2008) Molecular imaging of hypoxia. J Nucl Med 49(Suppl 2):129S–148S. doi:10.2967/jnumed.107.045914
29. Perche F, Biswas S, Wang T, Zhu L, Torchilin VP (2014) Hypoxia-Targeted siRNA Delivery. Angew Chem Int Ed Engl 53(13):3362–3366. doi:10.1002/anie.201308368
30. Biswas S, Dodwadkar NS, Piroyan A, Torchilin VP (2012) Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria. Biomaterials 33(18):4773–4782. doi:10.1016/j.biomaterials.2012.03.032
31. Thoma CR, Zimmermann M, Agarkova I, Kelm JM, Krek W (2014) 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv Drug Deliv Rev 69–70:29–41. doi:10.1016/j.addr.2014.03.001
32. Mehta G, Hsiao AY, Ingram M, Luker GD, Takayama S (2012) Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release 164(2):192–204. doi:10.1016/j.jconrel.2012.04.045
33. Perche F, Patel NR, Torchilin VP (2012) Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release 164(1):95–102. doi:10.1016/j.jconrel.2012.09.003
34. Huang L, Liu Y (2011) In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 13:507–530. doi:10.1146/annurev-bioeng-071910-124709
35. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675
36. Waite CL, Roth CM (2009) PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem 20(10):1908–1916. doi:10.1021/bc900228m
37. Kieda C, El Hafny-Rahbi B, Collet G, Lamerant-Fayel N, Grillon C, Guichard A, Dulak J, Jozkowicz A, Kotlinowski J, Fylaktakidou KC, Vidal A, Auzeloux P, Miot-Noirault E, Beloeil JC, Lehn JM, Nicolau C (2013) Stable tumor vessel normalization with pO(2) increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J Mol Med (Berl) 91(7):883–899. doi:10.1007/s00109-013-0992-6
38. Tupper J, Greco O, Tozer GM, Dachs GU (2004) Analysis of the horseradish peroxidase/ indole-3-acetic acid combination in a threedimensional tumor model. Cancer Gene Ther 11(7):508–513. doi:10.1038/sj.cgt.7700713
39. Zhu L, Wang T, Perche F, Taigind A, Torchilin VP (2013) Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cellpenetrating moiety. Proc Natl Acad Sci U S A 110(42):17047–17052. doi:10.1073/pnas.1304987110
40. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG, Jove R, Pardoll D, Yu H (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11(12):1314–1321. doi:10.1038/nm1325
41. Perche F, Lambert O, Berchel M, Jaffres PA, Pichon C, Midoux P (2012) Gene transfer by histidylated lipopolyplexes: a dehydration method allowing preservation of their physicochemical parameters and transfection efficiency. Int J Pharm 423(1):144–150. doi:10.1016/j.ijpharm.2011.04.009
42. Primon M, Huszthy PC, Motaln H, Talasila KM, Torkar A, Bjerkvig R, Lah Turnsek T (2013) Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids. Exp Cell Res 319(17):2637–2648. doi:10.1016/j.yexcr.2013.08.011